Choice • Flexibility • Specialization
Spanning three cities—Brisbane, Melbourne and Minneapolis—we are unmatched in our capabilities, experience, and ability to offer specialized Phase 1 facilities for early phase clinical trial designs. This is great news for Biotechnology, Pharmaceutical and CROs around the globe.
Our Phase 1 facilities are strategically co-located within prominent Australian Hospitals or within a Life Sciences and Biomedical Research Precinct, and each of our facilities have the necessary security and equipment to safely conduct the most complex of early phase clinical trials. This includes:
All housed whithin a secure video surveillance facility.
The Phase 1 facilities also include dedicated in-house sample processing laboratories and in-house pharmacy clean rooms.
Our Brisbane facility is Australia’s second-largest Phase 1 clinical trials facility, housing a total of 60 beds.
Specializing in vaccine and biosimilar studies, our Brisbane facility has purpose-built infrastructure to support the high-volume participant and outpatient requirements of these clinical trial designs. This facility is also supported by external bioanalytical and pharmacodynamic laboratories. The Brisbane facility features:
Our Melbourne facility is Australia’s largest Phase 1 clinical trials facility in the country, housing a total of 94 beds.
Specializing in first in human clinical trials, our Melbourne facility has extensive pharmacodynamic biomarker capabilities, including on-site access to imaging facilities, respiratory facilities (bronchoscopy suites), gastroenterology facilities (endoscopy suites) and anaesthetic services (lumbar punctures and pain models).
Pharmacodynamic capabilities also extend to immunology services (including flow cytometry and immune activation) and bioanalytical services through onsite external vendors. Other benefits of note include:
Our Minneapolis 50 bed Phase 1 facility is located in the heart of the Minneapolis metropolitan area and specializes in the conduct of healthy studies as well as complex patient studies, including onsite dialysis for patients with severe renal impairment.
The long-term partnerships with private clinicians and speciality groups throughout Minnesota provides us with unique access to various patient populations not readily available in other Phase 1 facilities. This capability, coupled with healthy volunteer expertise, make our Minneapolis Phase 1 facility an ideal location for conducting early phase clinical trials. Other benefits of the facility include: